Research statistics

MK-677 research: publications and trials

What has been published on MK-677: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether MK-677 works or is safe. For what it is and what the studies found, see the MK-677 profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

81

Since 1995

Publications in 2026 so far

1

Through November 15, 2026

Human clinical research

28.8%

23 of 80 classified

Registered clinical trials

3

ClinicalTrials.gov

Randomized controlled trials

17

Publications reporting an RCT in people

Systematic reviews and meta-analyses

0

Preclinical studies

50.0%

27 animal · 13 in vitro · 0 computational

Records that only mention it

56

Not counted above

Status in the library: Research only. Groups: Growth hormone axis. 1 publications are not yet classified by study type.

What to keep in mind

  • Some completed trials have neither posted results nor a linked results publication.
  • Not a peptide: it is shown for completeness and left out of every peptide total.

Publications by year

MK-677 publications by year and evidence

1995, Preclinical (animal, in vitro, computational): 1 of 11996, Human clinical research: 2 of 61996, Preclinical (animal, in vitro, computational): 3 of 61996, Reviews and meta-analyses: 1 of 61997, Human clinical research: 3 of 91997, Preclinical (animal, in vitro, computational): 4 of 91997, Reviews and meta-analyses: 1 of 91997, Other and not yet classified: 1 of 91998, Human clinical research: 3 of 71998, Preclinical (animal, in vitro, computational): 2 of 71998, Reviews and meta-analyses: 2 of 71999, Human clinical research: 3 of 91999, Preclinical (animal, in vitro, computational): 5 of 91999, Reviews and meta-analyses: 1 of 92000, Preclinical (animal, in vitro, computational): 2 of 22001, Human clinical research: 2 of 32001, Reviews and meta-analyses: 1 of 32002, Preclinical (animal, in vitro, computational): 2 of 22003, Human clinical research: 1 of 22003, Preclinical (animal, in vitro, computational): 1 of 22004, Human clinical research: 1 of 22004, Preclinical (animal, in vitro, computational): 1 of 22005, Preclinical (animal, in vitro, computational): 1 of 22005, Reviews and meta-analyses: 1 of 22006, Preclinical (animal, in vitro, computational): 1 of 12007, Reviews and meta-analyses: 1 of 12008, Human clinical research: 2 of 52008, Preclinical (animal, in vitro, computational): 1 of 52008, Other and not yet classified: 2 of 52009, Preclinical (animal, in vitro, computational): 1 of 42009, Other and not yet classified: 3 of 42010, Human clinical research: 1 of 12013, Preclinical (animal, in vitro, computational): 1 of 12017, Reviews and meta-analyses: 1 of 12018, Human clinical research: 1 of 32018, Preclinical (animal, in vitro, computational): 2 of 32019, Preclinical (animal, in vitro, computational): 1 of 12020, Preclinical (animal, in vitro, computational): 3 of 42020, Reviews and meta-analyses: 1 of 42021, Preclinical (animal, in vitro, computational): 2 of 22022, Human clinical research: 2 of 52022, Preclinical (animal, in vitro, computational): 3 of 52024, Preclinical (animal, in vitro, computational): 1 of 12025, Human clinical research: 2 of 52025, Preclinical (animal, in vitro, computational): 2 of 52025, Reviews and meta-analyses: 1 of 52026 (to date), Reviews and meta-analyses: 1 of 1Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified051019952001200720182026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
199501001
199623106
199734119
199832207
199935109
200002002
200120103
200202002
200311002
200411002
200501102
200601001
200700101
200821025
200901034
201010001
201301001
201700101
201812003
201901001
202003104
202102002
202223005
202401001
202522105
2026 (to date)00101

Study types

Animal study27
Randomized controlled trial17
In vitro study13
Review12
Editorial, letter or other5
Other clinical trial4
Case report2
Not yet classified1

Research areas

From MeSH major topics. A paper can be in several areas.

Endocrinology33
Neurological and mental health23
Metabolic health18
Longevity and aging10
Musculoskeletal10
Obesity and weight management8
Tissue repair7
Cardiovascular5
Cognitive health3
Oncology3
Antimicrobial and infectious disease2
Dermatology2

Registered clinical trials

1 of 2 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 3
Phase 1 / Phase 2: 1 · Phase 2: 2

TrialStatusPhaseStartedResults
The Impact of Ibutamoren on Nonalcoholic Fatty Liver DiseaseNCT05364684 · 12 enrolledCompletedPhase 22022-08Posted
Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of FibromyalgiaNCT00116129 · 64 enrolledCompletedPhase 22005-07—
Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older AdultsNCT00474279 · 72 enrolledCompletedPhase 1, Phase 21998-07—

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · March 1, 2018 · Randomized controlled trial · cited 24 times · open access

    PMID 28340044 · DOI 10.1093/ndt/gfw474 · Human clinical research

  2. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.

    Archives of gerontology and geriatrics · November 9, 2010 · Randomized controlled trial · cited 67 times

    PMID 21067829 · DOI 10.1016/j.archger.2010.10.004 · Human clinical research

  3. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.

    Annals of internal medicine · November 1, 2008 · Randomized controlled trial · cited 255 times · open access

    PMID 18981485 · DOI 10.7326/0003-4819-149-9-200811040-00003 · Human clinical research

  4. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.

    Neurology · November 1, 2008 · Randomized controlled trial · cited 91 times

    PMID 19015485 · DOI 10.1212/01.wnl.0000335163.88054.e7 · Human clinical research

  5. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture.

    Journal of the American Geriatrics Society · April 1, 2004 · Randomized controlled trial · cited 83 times

    PMID 15066065 · DOI 10.1111/j.1532-5415.2004.52156.x · Human clinical research

  6. The effect of treatment with the oral growth hormone (GH) secretagogue MK-677 on GH isoforms.

    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · February 1, 2003 · Randomized controlled trial · cited 3 times

    PMID 12550076 · DOI 10.1016/s1096-6374(02)00138-7 · Human clinical research

  7. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.

    Clinical pharmacology and therapeutics · July 1, 2001 · Randomized controlled trial · cited 34 times

    PMID 11452249 · DOI 10.1067/mcp.2001.116514 · Human clinical research

  8. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.

    The Journal of clinical endocrinology and metabolism · March 1, 2001 · Randomized controlled trial · cited 79 times

    PMID 11238495 · DOI 10.1210/jcem.86.3.7294 · Human clinical research

  9. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · July 1, 1999 · Randomized controlled trial · cited 50 times · open access

    PMID 10404019 · DOI 10.1359/jbmr.1999.14.7.1182 · Human clinical research

  10. Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a).

    The Journal of clinical endocrinology and metabolism · June 1, 1999 · Randomized controlled trial · cited 13 times

    PMID 10372705 · DOI 10.1210/jcem.84.6.5799 · Human clinical research

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT.

    The Journal of cell biology · December 16, 2002 · Animal study · cited 724 times · open access

    PMID 12486113 · DOI 10.1083/jcb.200207165 · Animal studies

  2. Molecular analysis of rat pituitary and hypothalamic growth hormone secretagogue receptors.

    Molecular endocrinology (Baltimore, Md.) · April 1, 1997 · In vitro study · cited 358 times · open access

    PMID 9092793 · DOI 10.1210/mend.11.4.9908 · In vitro studies

  3. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue.

    Proceedings of the National Academy of Sciences of the United States of America · July 1, 1995 · Animal study · cited 327 times · open access

    PMID 7624358 · DOI 10.1073/pnas.92.15.7001 · Animal studies

  4. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.

    The Journal of clinical endocrinology and metabolism · December 1, 1996 · Randomized controlled trial · cited 275 times

    PMID 8954023 · DOI 10.1210/jcem.81.12.8954023 · Human clinical research

  5. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.

    Annals of internal medicine · November 1, 2008 · Randomized controlled trial · cited 255 times · open access

    PMID 18981485 · DOI 10.7326/0003-4819-149-9-200811040-00003 · Human clinical research

Latest publications

  1. Peptide Supplements and Their Therapeutic Applications in Sports Medicine.

    The American journal of sports medicine · August 11, 2026 · Review · cited 1 times · open access

    PMID 42578445 · DOI 10.1177/03635465261464420 · Reviews and meta-analyses

  2. Acute stress suppresses hunger-driven food seeking through PVN activation: Reversal by anxiolytic drug and ghrelin receptor agonist, with anxiolytic-like effects of refeeding.

    Neuroscience research · November 17, 2025 · Animal study · cited 0 times · open access

    PMID 41260416 · DOI 10.1016/j.neures.2025.104989 · Animal studies

  3. Knowing the minimal detectable dose can facilitate the interpretation of a hair test result: II. Case example with ibutamoren (MK-677), a growth hormone secretagogue.

    Clinica chimica acta; international journal of clinical chemistry · August 27, 2025 · Other clinical trial · cited 1 times

    PMID 40882886 · DOI 10.1016/j.cca.2025.120578 · Human clinical research

  4. Hepatotoxicity induced by MK-677.

    BMJ case reports · July 17, 2025 · Case report · cited 1 times

    PMID 40675653 · DOI 10.1136/bcr-2025-265728 · Human clinical research

  5. Investigating the P53-dependent anti-cancer effect of ibutamoren in human cancer cell lines.

    Basic & clinical pharmacology & toxicology · January 1, 2025 · In vitro study · cited 0 times

    PMID 39668330 · DOI 10.1111/bcpt.14111 · In vitro studies

  6. New directions in growth hormone treatment in children.

    Pediatric endocrinology, diabetes, and metabolism · January 1, 2025 · Review · cited 1 times · open access

    PMID 41693185 · DOI 10.5114/pedm.2025.158544 · Reviews and meta-analyses

  7. GHSR signalling in perinatal phases is involved in liver metabolism at puberty.

    The Journal of endocrinology · August 12, 2024 · Animal study · cited 1 times

    PMID 39045853 · DOI 10.1530/joe-24-0039 · Animal studies

  8. Detection of the growth hormone secretagogue MK-0677 in equine hair following oral administration.

    Drug testing and analysis · December 19, 2022 · Animal study · cited 6 times

    PMID 36354265 · DOI 10.1002/dta.3406 · Animal studies

  9. LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report.

    Experimental physiology · November 16, 2022 · Case report · cited 12 times · open access

    PMID 36303408 · DOI 10.1113/ep090741 · Human clinical research

  10. Characterization of growth hormone secretagogue small molecule ibutamoren (MK-0677) and its possible metabolites in thoroughbred horses for doping control.

    Rapid communications in mass spectrometry : RCM · September 1, 2022 · Animal study · cited 9 times

    PMID 35716382 · DOI 10.1002/rcm.9337 · Animal studies

Browse all 81 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: Ibutamoren; MK-677; Nutrobal

((TITLE_ABS:"Ibutamoren" OR CHEM:"Ibutamoren") OR (TITLE_ABS:"MK-677" OR CHEM:"MK-677" OR TITLE_ABS:"MK677" OR CHEM:"MK677") OR (TITLE_ABS:"Nutrobal" OR CHEM:"Nutrobal")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). MK-677 research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/mk-677